Serological response to influenza vaccine in patients with autoimmune inflammatory diseases: Results of RIER study

Background: Influenza vaccine is recommended for patients with autoimmune inflammatory diseases (AIID) on biological therapy. Objective: To evaluate whether serological response to Influenza vaccine obtained in patients on biological therapy is similar to that achieved in patients on synthetic disease-modifying anti-rheumatic drugs (DMARDs) and that obtained in healthy controls. Methods: We designed a cohort study in which patients with AIID, 68 on biological therapy and 46 on synthetic DMARDs, as well as 48 healthy controls, were included and vaccinated during the 2015-2016 influenza season. ELISA was used to measure Influenza antigen (Ag) A and B antibodies, before and after vaccination. Results: After vaccination, 88.24% of patients on biologics, 71.74% of those on synthetic DMARDs and 89.58% of healthy controls, presented detectable antibodies against antigen A, while 42.65% of subjects on biologics, 41.30% of those on DMARDs and 54.17% of healthy subjects were seropositive against Ag B. We did not find statistical differences. Conclusions: In our study, biological therapy is not associated with worse serological response.Sin financiación3.200 JCR (2021) Q2, 75/172 Medicine, General & Internal0.325 SJR (2021) Q3, 1635/2489 Medicine (Miscellaneous)No data IDR 2021UE